Bristol Myers (BMY.US) and Prime Medicine (PRME.US) collaborate to develop innovative cell therapies
AInvestWednesday, Oct 2, 2024 8:30 pm ET
1min read
MYE --
PRME --

Prime Medicine (PRME.US) announced on September 30 that it has entered into a strategic development and license agreement with Bristol Myers (BMY.US) to co-develop next-generation T-cell therapies, combining Prime Medicine's precise multi-gene editing capabilities with Bristol Myers' expertise in developing and commercializing innovative cell therapies.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.